Advances presented at the second edition of the International RIETE Meeting

On October 19th and 20th, Seville hosted the 2nd International RIETE Meeting, where the latest scientific advances on the relationship between cancer and thrombosis were presented.

Nearly 200 doctors and healthcare professionals attended the meeting, in which several studies were communicated that had been carried out using the RIETE Registry, which now has information on more than 72,000 patients with venous thromboembolism (VTE) from 25 countries.

Highlights of the meeting:

• Implementationof the Cancer and Thrombosis White Paper, prepared last year, in different countries of the European Union.
• For the first time, a study has analysed the evolution of patients with cancer and VTE under anticoagulant treatment for more than six months. Notably, it found that if anticoagulant treatment is extended for more than half a year, it improves patients’ survival (anticoagulants are usually administered for three or six months, no longer).
• Another study found for the first time that the administration of direct-acting oral anticoagulants(DOACs) can be at least as safe and effective as standard anticoagulant treatment (with low-molecular-weight heparin) in patients with cancer and VTE.
• In patients with VTE who bleed due to anticoagulant treatment, after the first 48 hours the risk of VTE recurrence is greaterthan the risk of bleeding recurrence.
• Inferior vena cava filters improve the survivalof patients with VTE who bleed due to anticoagulant treatment.